![ATOM_HPSlider_DOCandPILLS_FIN](http://atombp.us/wp-content/plugins/revslider/sr6/assets/assets/dummy.png)
![ATOM_HPSlider_womanwithbluetubeDRAFT_Flipped](http://atombp.us/wp-content/plugins/revslider/sr6/assets/assets/dummy.png)
![ATOM_HPSlider_FORUMULA_FIN](http://atombp.us/wp-content/plugins/revslider/sr6/assets/assets/dummy.png)
Learn the impact gout may have on millions of lives.
Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.) is a clinical stage biotechnology company founded in 2012. Atom is developing best-in-class orally delivered small molecule drugs for treatment of inflammatory and metabolic diseases, such as chronic gout, acute gout and others for which there are no effective treatments.
![](https://atombp.us/wp-content/themes/u-design/assets/images/lazy.png)
![](https://atombp.us/wp-content/themes/u-design/assets/images/lazy.png)
Atom’s lead product, ABP-671, is in multicenter Phase 2b/3 clinical trials worldwide, including the US, for treatment of chronic gout. ABP-671 has shown good efficacy, safety and tolerability in completed clinical trials. It is more potent and significantly less toxic than existing drugs.
Another small molecule, ABP-745, has shown significant efficacy and good safety in animal models of anti-inflammation. ABP-745 has also demonstrated safety and efficacy in pre-clinical trials for acute gout and other anti-inflammation diseases and is in Phase 1 clinical trials.
Learn how and why Atom Bioscience is developing new treatments for gout — and the impact it may have on millions of lives.
Latest News from Atom Bioscience
21 April, 2024